A new trial is recruiting participants to evaluate the use of calcium dobelisate as a combination therapy, along with Pulse Dye Laser to treat the erythema, flushing and telangectasia associated with erythematotelangietatic rosacea. We know from rosacea and doxium that “Calcium dobesilate is a vasoactive drug with presumed effects on endothelial integrity, capillary permeability and blood viscosity.”
Clinical Trial NCT00945373: Combination Therapy for the Treatment of Rosacea
The purpose of this study is to determine the efficacy of calcium dobesilate in combination with pulsed dye laser for the treatment of rosacea.
Drug: calcium dobesilate 2.5% gel
Procedure: pulsed dye laser
All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
Several studies have shown successful treatment of rosacea-associated telangiectasia and erythema with pulsed dye laser. Moreover, calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a drug that inhibits vascular smooth muscle cell growth and inhibits cellular proliferation. As a synthetic inhibitor of fibroblast growth factor (FGF), calcium dobesilate targets angiogenic growth factors which lead to uncontrolled blood vessel growth. In light of the fact that angiogenesis has been implicated in erythematotelangietatic rosacea, calcium dobesilate will be useful in the treatment of this subtype of rosacea.
Thus, combination treatment with PDL and calcium dobsilate will act in a synergistic manner to reduce the erythema, flushing and telangectasia associated with erythematotelangietatic rosacea.
How do I identify that I want to participate?
The clinicaltrials.gov page linked above has contact information for those conducting the trial.
dp.